Evidence map›Paper›PMID 30976788›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Rates of New Human Immunodeficiency Virus (HIV) Diagnoses After Reported Sexually Transmitted Infection in Women in Louisiana, 2000-2015: Implications for HIV Prevention.

Daniel R Newman, Mohammad M Rahman, Antoine Brantley, Thomas A Peterman

Open access · hybridAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Intersecting Epidemics: Incident Syphilis and Drug Use in Women Living With Human Immunodeficiency Virus in the United States (2005-2016).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Daniel R NewmanDivision of sexually transmitted diseases (STD) Prevention, National Center for Human Immunodeficiency Virus (HIV), Hepatitis, STD, and tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
Mohammad M RahmanDivision of sexually transmitted diseases (STD) Prevention, National Center for Human Immunodeficiency Virus (HIV), Hepatitis, STD, and tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
Antoine BrantleySTD/HIV Program, Louisiana Department of Health, New Orleans.
Thomas A PetermanDivision of sexually transmitted diseases (STD) Prevention, National Center for Human Immunodeficiency Virus (HIV), Hepatitis, STD, and tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
Louisiana State Department of Health and Hospitals · USNational Center for HIV/AIDS Viral Hepatitis STD and TB Prevention · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundHuman immunodeficiency virus (HIV) prevention interventions for prevention interventions for women include screening, partner notification, promoting condoms, and preexposure prophylaxis (PrEP). Women's risk of acquiring HIV can help guide recommendations.

methodsWe used data from Louisiana's sexually transmitted infection (STI) and HIV registries to study 13- to 59-year-old women following first diagnosis of syphilis, gonorrhea, or chlamydia during 2000-2015. We measured HIV rates reported subsequent to STI (through 2016). Rates for women without STI were estimated by subtracting women with STI from reported cases and from Census estimates for the population. PrEP cost was estimated as $11 000 per year, and effectiveness estimated as 100%.

resultsSTIs were syphilis (6574), gonorrhea (64 995), or chlamydia (140 034). These 211 603 women had 1 865 488 person-years of follow-up and 969 HIV diagnoses. Women with no STI had 5186 HIV diagnoses over 24 359 397 person-years. HIV rates diagnosis (per 100 000 person-years) were higher for women after syphilis (177.3), gonorrhea (73.2), or chlamydia (35.4) compared to women with no STI (22.4). Providing PrEP to all women diagnosed with syphilis or gonorrhea would cost $7 371 111 000 and could have prevented 546 HIV diagnoses. Limiting PrEP to 1 year after syphilis or gonorrhea diagnosis would cost $963 847 334, but only 143 HIV diagnoses were within 2 years after a syphilis or gonorrhea diagnosis.

conclusionsRates of HIV diagnosis were high after women had STI, but not high enough to make PrEP cost-effective for them. Most women diagnosed with HIV did not have previously reported STI.

Indexed as

Chlamydia InfectionsGonorrheaHIV InfectionsPre-Exposure ProphylaxisSexually Transmitted DiseasesSyphilisAdolescentAdultFemaleHIVHumansLouisianaMiddle AgedYoung AdultHIVPrEPpreventionSTIwomen

Identifiers

PMID30976788
PMCPMC6790153
OpenAlexW2940053325

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.